AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc., an integrated molecular diagnostic company and provider of clinical laboratory services, today announced it has been awarded accreditation by the Laboratory Accreditation Program of the College of American Pathologists (CAP). This is based on results of a recent on-site inspection of Asuragen’s Clinical Laboratory Improvement Amendments (CLIA) - compliant laboratory. CAP laboratory requirements are among the most stringent, and accreditation with the organization indicates compliance with the highest standards of quality for complex molecular testing. The accreditation is a crucial step for Asuragen in commercializing miRNA-based oncology tests and conducting clinical sample testing for its pharmaceutical clients. The miRNA Pancreatic FFPE Test for aid in diagnosis of pancreatic adenocarcinoma is Asuragen’s first commercially available CLIA-based test.
